Goals and objectives in the management of metastatic breast cancer.
about
Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancerPalliative medicine and decision science: the critical need for a shared agenda to foster informed patient choice in serious illnessTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasisDoes multidisciplinary care enhance the management of advanced breast cancer?: evaluation of advanced breast cancer multidisciplinary team meetings.The paradox of response and survival in cancer therapeuticsDeletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion.Metastatic breast cancer in a Nigerian tertiary hospital.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysisTreatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast CancerClinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.Sexual well-being among partnered women with breast cancer recurrence.Health state utilities for metastatic breast cancer.Bromodomain 4 activation predicts breast cancer survivalThe Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survivalPsychosocial influences on suboptimal adjuvant breast cancer treatment adherence among African American women: implications for education and intervention.Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone'Being there' for women with metastatic breast cancer: a pan-European patient survey.Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.Treatment options for breast cancer and bone metastases.Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.The Complex Interaction of Matrix Metalloproteinases in the Migration of Cancer Cells through Breast Tissue Stroma.Treatment of metastatic breast cancer: second line and beyond.Glucose-regulated protein 94 modulates the therapeutic efficacy to taxane in cervical cancer cells.Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.Submental lymph node metastasis from invasive ductal breast carcinoma.Making sense of living under the shadow of death: adjusting to a recurrent breast cancer illness.The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer.Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.
P2860
Q21195235-319261B8-D0A2-450C-862E-83AA01C232CDQ24629373-0352DBE2-39B7-4E03-B428-638A706A6AEDQ26745420-AC88F3C9-7447-42BB-82B4-4C0080B1A913Q34076147-B5417506-137B-4E32-993E-4259BFE23B62Q34335073-AEBA4003-EB38-4B0E-AC45-4024B5A2CFA1Q34449433-12A1D997-F758-455C-B8B5-D08890D86C5BQ34803675-84699CB6-46AF-4F87-99AB-D4BED290EB3DQ35171957-1F292566-EA88-4814-A69E-C0E45770F387Q35507680-67D45CFB-2D0B-46F6-9247-A0D89385FC5BQ35541901-452105C6-6DBD-493D-B48B-6B8A90D50B71Q35687540-72380A71-59ED-4FB7-9205-8D4F38C48C57Q36028961-7E8C615C-8EF2-48FA-BEE0-5F8C7EF3428EQ36072794-F1033FB4-0961-4E61-93F3-3C8B5D10CB14Q36293902-639812E0-4CBA-48F3-A5A4-E87C7AB73A63Q36591214-AF1D9F6E-922E-4FD5-94C8-2A1F0AB365EAQ36609000-F1B05300-F1B8-4116-8115-72A94B1CD7BCQ36696198-A444E548-4B1D-4821-8A26-164961127F64Q36957306-67AB672D-C81B-4D56-A0DA-D9579BEFB0C8Q37152795-F822FF63-8FC8-45F3-8564-5DD93B3D099BQ37182271-0E0F897C-AE36-4134-BF42-0F8CE026D5E0Q37236305-EE2C6977-47D1-4DB4-A3A9-70165D935DCAQ37332275-08C17068-3C91-4BF5-94CB-395DBBFBDD8CQ37401841-CBB3AF15-A058-42AB-892F-2CB4F666EBEBQ37589074-03C30F2E-9FEE-434A-909F-93A02FE806EDQ37700768-BC332465-186C-41C9-A6F4-E54E82A127EBQ37802108-E3F760CC-7BCC-4235-8ED9-264F8EC520FCQ39113189-BF26F4D1-1346-4B36-85B7-34FD17A16554Q39185424-D22F89A1-8CA4-452C-808E-32CB61B5BE19Q47830773-50199E32-240D-4DE1-A29A-A99F00AFAA35Q48909132-1991633E-E5F4-436B-9C59-E51700516248Q49111429-E5018B97-B18C-4C43-81EA-A7464217F74BQ52687764-DA477113-FB43-4E4E-8638-5DDE2E692E22Q54308667-181869B2-11BF-4974-AE34-AF6771C71B9D
P2860
Goals and objectives in the management of metastatic breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Goals and objectives in the management of metastatic breast cancer.
@ast
Goals and objectives in the management of metastatic breast cancer.
@en
type
label
Goals and objectives in the management of metastatic breast cancer.
@ast
Goals and objectives in the management of metastatic breast cancer.
@en
prefLabel
Goals and objectives in the management of metastatic breast cancer.
@ast
Goals and objectives in the management of metastatic breast cancer.
@en
P1433
P1476
Goals and objectives in the management of metastatic breast cancer.
@en
P2093
Cathie T Chung
Robert W Carlson
P304
P356
10.1634/THEONCOLOGIST.8-6-514
P577
2003-01-01T00:00:00Z